Home > Business Cases > Understanding the mechanism of action and future cardiotoxicity of new drugs
Understanding the mechanism of action and future cardiotoxicity of new drugs
Situation
Some compounds of the class orexin receptor antagonists tend to produce cardiotoxicity. A client with new NCE in the same class had to prove to regulatory agencies that cardiotoxicity was not likely to occur for their product.
Anaxomics Strategy
Client's new compound had a different target profile from other drugs in the class. Besides orexins A and B, the other compounds in the class (or their metabolites) had different additional targets from client's compound.
Anaxomics created the biological network around known targets of all compounds, including 1000+ nodes and milions of interactions. We developed a model that explained the observed behaviour of more than 100 known drugs whose targets where contained in the network
Solution and Practical Use
Using the same network and model that explained the behaviour of known drugs, we predicted that the Client's compound was not likely to produce cardiotox, because of its different target profile. After analyzing how the mechanistic model was build, regulatory agency agreed that the Client's compound was not likely to produce cardiotox, because targets and pathways involved where different.
Please, contact us here to request more information.
